Contents
1. Myelodysplastic Syndrome (MDS): How common is it? i.e. epidemiology and risk factors. E Estey, MD Anderson (soon to move to Fred Hutchinson Cancer Centre, Seattle). 2. Therapy related myelodysplasia. Predisposing factors and molecular genetics J. Pederson-Bjergaard, Denmark. 3. Cytogenetic abnormalities in primary and secondary MDS D. Haase, Gottingen, Germany 4. The value of SNP and expression profiling in diagnosis and prognosis Mufti GJ 5. Molecular pathology of 5q-syndrome and 5q- abnormality Benjamin Ebert, Dana Farber, Boston 6. Genomic instability syndromes and myelodysplasia Inderjeet Dokal, Barts and The London 7. Animal models of myelodysplasia. Timothy Graubert, Saint Louis 8. Biological defects of haemopoiesis of low risk MDS Eva Hellstrom-Lindberg - Sweden 9. Prognostic evaulation of primary MDS Ulrich Germing, Germany 10. FAB, WHO, IWG and beyond John Bennett, Rochester 11. Methylation and histone acetylation in the context of MDS Steve Gore, Johns Hopkins 12. Treatment of MDS with demethylating agents and HDAC inhibitor Hagop Kantarjian, MD Anderson 13. Supportive treatment in low and high risk MDS Pierre Fenaux, Paris 14. Allogeneic stem cell transplantation in MDS Ziyi Lim and Theo De Witte 15. Immune dysregulation and immunosuppressive therapy MDS Shahram Kordasti, King's College London 16. Aplastic anaemia/MDS overlap syndrome Neil Young, NIH 17. Clinical and molecular spectrum of Myeloproliferative/Myelodysplastic disorders (MPD/MDS) Ayalew Tefferi, Mayo Clinic 18. MPD/MDS overlap syndromes Michael McDevitt 19. Adult and juvenile Chronic Myelomonocytic Leukemia (CMML) Christine Neimyer and _ Steenma 20. Emerging therapies including Lenolidamide Alan List, Tampa, Florida
